Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
G GENITO URINARY SYSTEM AND SEX HORMONES
G04 UROLOGICALS
G04C DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
G04CA Alpha-adrenoreceptor antagonists
G04CA04 Silodosin
D01965 Silodosin (JP18/INN) <JP/US>
USP drug classification [BR:br08302]
Genitourinary Agents
Benign Prostatic Hypertrophy Agents
Silodosin
D01965 Silodosin (JP18/INN)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
25 Urogenital and anal organ agents
259 Miscellaneous
2590 Miscellaneous
D01965 Silodosin (JP18/INN)
Drug groups [BR:br08330]
Cardiovascular agent
DG01466 Adrenergic receptor antagonist
DG01465 alpha-Adrenergic receptor antagonist
DG01457 alpha1-Adrenergic receptor antagonist
D01965 Silodosin
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D01965 Silodosin
DG02924 UGT substrate
D01965 Silodosin
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Adrenaline
ADRA1A
D01965 Silodosin (JP18/INN) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D01965 Silodosin
D01965 Silodosin tablets
D01965 Silodosin orally disintegrating tablets
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D01965
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D01965
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D01965
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D01965
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D01965